FibroStatin SL:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:FibroStatin SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11219
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
FibroStatin SL (FibroStatin) is a drug development company that focuses on the development of treatment candidates for drug resistant lung cancer and idiopathic pulmonary fibrosis. The company’s pipeline products include T12/FST12 for NSCLC, GPBP-Mab/FSM26 for idiopathic pulmonary fibrosis and diabetes, and GPBP Inhibitor for renal diseases. It also develops GPBP specific monoclonal antibodies that target the high molecular weight oligomers of GPBP that are active during EMT. FibroStatin’s activities include protein chemistry, molecular and cell biology, organic chemistry, histopathology and mass spectrometry. The company partners with pharmaceutical and biotechnology companies to advance its treatment candidate through clinical trials. FibroStatin is headquartered in Valencia, Spain.

FibroStatin SL – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
FibroStatin SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FibroStatin SL, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
FibroStatin SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FibroStatin SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
FibroStatin SL, Medical Devices Deals, 2012 to YTD 2018 9
FibroStatin SL, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
FibroStatin SL, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Fibrostatin Enters into Co-Development Agreement with 12th October University Hospital 11
Fibrostatin Enters into Research Agreement with La Paz University Hospital 12
Fibrostatin Enters into Co-Development Agreement with Marques de Valdecilla 13
Licensing Agreements 14
Fibrostatin Enters into Licensing Agreement with Boehringer Ingelheim 14
FibroStatin SL – Key Competitors 15
FibroStatin SL – Key Employees 16
FibroStatin SL – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
FibroStatin SL, Pharmaceuticals & Healthcare, Key Facts 2
FibroStatin SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FibroStatin SL, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
FibroStatin SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FibroStatin SL, Deals By Therapy Area, 2012 to YTD 2018 8
FibroStatin SL, Medical Devices Deals, 2012 to YTD 2018 9
FibroStatin SL, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Fibrostatin Enters into Co-Development Agreement with 12th October University Hospital 11
Fibrostatin Enters into Research Agreement with La Paz University Hospital 12
Fibrostatin Enters into Co-Development Agreement with Marques de Valdecilla 13
Fibrostatin Enters into Licensing Agreement with Boehringer Ingelheim 14
FibroStatin SL, Key Competitors 15
FibroStatin SL, Key Employees 16

List of Figures
FibroStatin SL, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
FibroStatin SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
FibroStatin SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
FibroStatin SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
FibroStatin SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FibroStatin SL, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
FibroStatin SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FibroStatin SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
FibroStatin SL, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[FibroStatin SL:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • University of Aberdeen-製薬・医療分野:企業M&A・提携分析
    Summary University of Aberdeen (UOA) is an educational and research institution that offers undergraduate, graduate, postgraduate and research programs in a range of subjects. The university offers undergraduate and postgraduate courses in the areas of arts, creative arts, commerce, education, engin …
  • Lannett Company Inc (LCI):製薬・医療:M&Aディール及び事業提携情報
    Summary Lannett Company Inc (Lannett) is a pharmaceutical company. It develops, manufactures and distributes generic prescription pharmaceutical products in tablet, capsule and oral liquid forms. The company offers generic pharmaceuticals for medical indications such as antibiotic, cardiovascular, c …
  • Andritz AG (ANDR):企業の財務・戦略的SWOT分析
    Andritz AG (ANDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • MedImmune LLC:企業のM&A・事業提携・投資動向
    MedImmune LLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's MedImmune LLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Under Armour Inc (UAA):企業の財務・戦略的SWOT分析
    Under Armour Inc (UAA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • STADA Arzneimittel AG:企業の戦略・SWOT・財務情報
    STADA Arzneimittel AG - Strategy, SWOT and Corporate Finance Report Summary STADA Arzneimittel AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Koninklijke Wessanen N.V.:戦略・SWOT・企業財務分析
    Koninklijke Wessanen N.V. - Strategy, SWOT and Corporate Finance Report Summary Koninklijke Wessanen N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Abu Dhabi National Energy Co (TAQA):石油・ガス:M&Aディール及び事業提携情報
    Summary Abu Dhabi National Energy Company (TAQA), a subsidiary of government-owned Abu Dhabi Water and Electricity Authority, is an energy and water company. It undertakes power generation; exploration, development, production and storage of oil and gas; pipelines and gas storage; and water desalina …
  • Stifel Financial Corp.:企業のM&A・事業提携・投資動向
    Stifel Financial Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Stifel Financial Corp. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Tel-Instrument Electronics Corp.:企業の戦略・SWOT・財務分析
    Tel-Instrument Electronics Corp. - Strategy, SWOT and Corporate Finance Report Summary Tel-Instrument Electronics Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • King Country Energy Ltd:企業の戦略的SWOT分析
    King Country Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Syros Pharmaceuticals Inc (SYRS):企業の財務・戦略的SWOT分析
    Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company’s pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used t …
  • LifeScan Inc-医療機器分野:企業M&A・提携分析
    Summary LifeScan Inc (LifeScan), a subsidiary of the Johnson & Johnson, develops, manufactures and markets blood glucose monitoring solutions for hospital and home use. The company’s product portfolio includes blood glucose meters; test strips and control solutions; lancing devices; diabetes managem …
  • NTN Corporation:企業の戦略・SWOT・財務分析
    NTN Corporation - Strategy, SWOT and Corporate Finance Report Summary NTN Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • WAVE Life Sciences Ltd (WVE):製薬・医療:M&Aディール及び事業提携情報
    Summary WAVE Life Sciences Ltd (WAVE Life Sciences), formerly WAVE Life Sciences Pte Ltd is a genetic medicine company that develops stereopure nucleic acid therapies. The company's pipeline products comprise multiple oligonucleotide modalities such as exon-skipping and single-stranded RNAi, and ant …
  • Vivimed Labs Ltd (VIVIMEDLAB):企業の財務・戦略的SWOT分析
    Vivimed Labs Ltd (VIVIMEDLAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • RentPath LLC:企業の戦略的SWOT分析
    RentPath LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • H.I.G. Capital LLC:企業の戦略的SWOT分析
    H.I.G. Capital LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Kanematsu Electronics Ltd (8096):企業の財務・戦略的SWOT分析
    Kanematsu Electronics Ltd (8096) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • DCC Plc (DCC):石油・ガス:M&Aディール及び事業提携情報
    Summary DCC Plc (DCC) is a diversified company that offers international sales, marketing, distribution and business support services. The company operates through its business divisions such as LPG, retail, and oil, healthcare and technology. Its LPG business markets liquefied petroleum gas and nat …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆